Wells Fargo Maintains Overweight on Celldex Therapeutics, Raises Price Target to $72

Benzinga Newsdesk www.benzinga.com Positive 85.6%

Neg 0% Neu 0% Pos 85.6%

Wells Fargo analyst Derek Archila maintains Celldex Therapeutics (NASDAQ:CLDX) with a Overweight and raises the price target from $48 to $72.